BACKGROUND Spleen enlargement is often detected in patients with liver cirrhosis, but the precise pathogenetic mechanisms behind the phenomenon have not been clearly elucidated. We investigated the pathogenetic mechanisms of splenomegaly in both portal hypertensive patients and rats, and tried to identify the possible therapy for this disease. METHODS Spleen samples were collected from portal...

"Big Spleen Disease"-Hamilton et al. MEBRITCLSH 825 44%. His only treatment has been a 15-day course of primaquine followed by 100 mg. of proguanil daily. This is further evidence for a malarial cause of this syndrome and also for implicating the spleen in the plasma volume changes. The role of the spleen is also shown by a case of Felty's syndrome (Pengelly, 1966), in which a marked reduction ...

Physician to the Bristol Royal Infirmary.

Patients with splenomegaly may come to medical attention for a variety of reasons. However, patients with no obvious explanation for an enlarged spleen present a difficult diagnostic problem. A detailed history taking, appropriate clinical examination and relevant investigations is tool for a diagnosis of splenomegaly. Appropriate investigations in most patients with undiagnosed splenomegaly wi...

Between 1978 and 1982, 14 patients underwent splenectomy for disabling massive splenomegaly at the Regency Hospital in Wamena in the highlands of Irian Jaya, Indonesia. All patients were clinically diagnosed as having tropical splenomegaly syndrome (hyperreactive malarial splenomegaly), but in no case was the diagnosis confirmed. In May 1984 nurses and physicians caring for these 14 patients we...

A controlled, randomized, double-blind trial of malaria prophylaxis in tropical splenomegaly syndrome showed a significant reduction in spleen size and an improvement of anaemia and symptoms in patients treated with antimalarials compared with control subjects receiving placebo. This study confirms the observations from West Africa and provides further indirect evidence for a malarial aetiology...

The Janus kinase (JAK) 1 and 2 inhibitor, ruxolitinib, was recently approved in Japan and has been effective in many patients with myelofibrosis (MF). Although the inhibitor decreases splenomegaly and relieves MF-related symptoms, allogeneic hematopoietic cell transplantation (HCT) remains as the only curative therapy for MF. The presence of splenomegaly has been reported as a risk factor for g...